Business Context and Reporting Period
Company: The Cooper Companies, Inc. (TCC)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended October 31, 1997
Headquarters: Pleasanton, California
TCC operates through three primary subsidiaries: CooperVision, Inc. (contact lenses), CooperSurgical, Inc. (diagnostic and surgical instruments), and Hospital Group of America, Inc. (HGA) (psychiatric facilities). The company employs approximately 1,400 people and operates in a highly regulated healthcare environment subject to FDA oversight and government reimbursement programs.
Key Financial Metrics
Note: Specific consolidated revenue, net income, cash flow, and debt figures are incorporated by reference from the 1997 Annual Report to Stockholders (Exhibit 13) and are not explicitly detailed in the provided text.
- Research & Development (R&D): $1.7 million for fiscal 1997 (up from $1.2 million in 1996 and $2.9 million in 1995).
- R&D Allocation: CooperVision incurred approximately 54% of total R&D; CooperSurgical incurred approximately 46%.
- Government Revenue Dependence (HGA): Medicaid and Medicare generated approximately 29% and 32% of HGA's net patient revenue, respectively.
- Allowance for Doubtful Accounts: Ended fiscal 1997 at $2,346,000 (up from $1,969,000 in 1996).
- Market Capitalization: Aggregate market value of voting stock held by non-affiliates was $589,841,619 as of December 31, 1997.
- Shares Outstanding: 14,799,705 shares as of December 31, 1997.
Material Changes and Operational Highlights
- R&D Spending: R&D expenditures increased by approximately 42% compared to the prior year ($1.7 million vs. $1.2 million).
- Corporate Structure: The company eliminated Series A Junior Participating Preferred Stock on October 30, 1997, and entered into a Rights Agreement on October 29, 1997.
- Seasonality: HGA occupancy rates decline during summer months and year-end holidays. CooperVision sales are typically lower in the first fiscal quarter due to holiday season patient visit patterns.
- Regulatory Environment: Continued emphasis on FDA compliance for Class III devices (contact lenses) and adherence to Medicare/Medicaid anti-fraud and abuse amendments.
Outlook, Risks, and Management Commentary
Forward-Looking Risks:
- Reimbursement Pressures: Significant limits on reimbursement rates and fees from government (Medicare/Medicaid) and private payors (managed care) could adversely affect HGA's earnings.
- Regulatory Approval: Delays or failures in obtaining FDA or foreign regulatory approvals for new products could impact revenue.
- Competition: Major competitors possess greater financial resources and larger R&D/sales forces, particularly in the contact lens and surgical segments.
- Healthcare Reform: Uncertainty regarding federal and state legislative initiatives that could alter the healthcare system, including price controls and insurance market reforms.
Management Strategy:
- CooperVision: Competes on product quality, service, and reputation, focusing on specialty niche markets and clinical studies.
- CooperSurgical: Focuses on distinct niche markets, offering comprehensive equipment and instrument solutions for specific medical procedures.
- HGA: Positions facilities as high-quality providers for specific disorders, utilizing program differentiation to attract referrals.
Investor Verification Checklist
- Verify the specific consolidated revenue, net income, and cash flow figures in the 1997 Annual Report to Stockholders (Exhibit 13), as they are not present in the 10-K text provided.
- Review the "Five Year Financial Highlights" in the Annual Report to assess long-term profitability trends.
- Examine Note 14 of the financial statements for detailed business segment performance (CooperVision, CooperSurgical, HGA).
- Assess the impact of the new Rights Agreement (Exhibit 4.2) on shareholder rights and potential dilution.
- Monitor updates on Medicare/Medicaid reimbursement rates and managed care contract negotiations affecting HGA's 61% government-dependent revenue stream.